Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

Michael Feher,1&ndash;3 Mark Greener,4 Neil Munro1&ndash;3,51Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, 2Diabetes Therapies Evaluation Network, London, 3CSRI, Warwick University, Warwick, 4ROCK Medical Communications, Richmond, 5Department of Health Care Man...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feher M, Greener M, Munro N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/4c3527219a6b492195168abc1ed0c729
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c3527219a6b492195168abc1ed0c729
record_format	dspace
spelling	oai:doaj.org-article:4c3527219a6b492195168abc1ed0c7292021-12-02T00:24:54ZPersistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/4c3527219a6b492195168abc1ed0c7292013-01-01T00:00:00Zhttp://www.dovepress.com/persistent-hypertriglyceridemia-in-statin-treated-patients-with-type-2-a11913https://doaj.org/toc/1178-7007Michael Feher,1&ndash;3 Mark Greener,4 Neil Munro1&ndash;3,51Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, 2Diabetes Therapies Evaluation Network, London, 3CSRI, Warwick University, Warwick, 4ROCK Medical Communications, Richmond, 5Department of Health Care Management, University of Surrey, Guildford, Surrey, UKPurpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the UK.Patients and methods: A cross-sectional, observational, systematic audit of patients with diagnosed diabetes from 40 primary care practices was undertaken. The audit collected basic demographic information and data on prescriptions issued during the preceding 4 months. T2DM patients were stratified according to the proportion that attained European Society of Cardiology treatment targets.Results: The audit collected data from 14,652 patients with diagnosed diabetes: 89.5% (n = 13,108) of the total cohort had T2DM. Of the people with T2DM, 22.2% (2916) were not currently receiving lipid-lowering therapy. Up to approximately 80% of these people showed evidence of dyslipidemia. Among the group that received lipid-lowering therapy, 94.7% (9647) were on statin monotherapy, which was usually simvastatin (69.5% of patients receiving statin monotherapy; 6707). The currently available statins were prescribed, with the most common dose being 40 mg simvastatin (44.2%; 4267). Irrespective of the statin used, around half of the patients receiving statin monotherapy did not attain the European Society of Cardiology treatment targets for triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol.Conclusion: T2DM patients managed in UK primary care commonly show persistent lipid abnormalities. Clinicians need to optimize compliance with lipid-lowering and other medications. Clinicians also need to consider intensifying statin regimens, prescribing additional lipid-modifying therapies, and specific treatments aimed at triglyceride lowering to improve dyslipidemia control in statin-treated patients with T2DM.Keywords: triglycerides, lipid-lowering treatment, diabetic dyslipidemia, simvastatin, auditFeher MGreener MMunro NDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 11-15 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Feher M Greener M Munro N Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
description	Michael Feher,1&ndash;3 Mark Greener,4 Neil Munro1&ndash;3,51Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, 2Diabetes Therapies Evaluation Network, London, 3CSRI, Warwick University, Warwick, 4ROCK Medical Communications, Richmond, 5Department of Health Care Management, University of Surrey, Guildford, Surrey, UKPurpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the UK.Patients and methods: A cross-sectional, observational, systematic audit of patients with diagnosed diabetes from 40 primary care practices was undertaken. The audit collected basic demographic information and data on prescriptions issued during the preceding 4 months. T2DM patients were stratified according to the proportion that attained European Society of Cardiology treatment targets.Results: The audit collected data from 14,652 patients with diagnosed diabetes: 89.5% (n = 13,108) of the total cohort had T2DM. Of the people with T2DM, 22.2% (2916) were not currently receiving lipid-lowering therapy. Up to approximately 80% of these people showed evidence of dyslipidemia. Among the group that received lipid-lowering therapy, 94.7% (9647) were on statin monotherapy, which was usually simvastatin (69.5% of patients receiving statin monotherapy; 6707). The currently available statins were prescribed, with the most common dose being 40 mg simvastatin (44.2%; 4267). Irrespective of the statin used, around half of the patients receiving statin monotherapy did not attain the European Society of Cardiology treatment targets for triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol.Conclusion: T2DM patients managed in UK primary care commonly show persistent lipid abnormalities. Clinicians need to optimize compliance with lipid-lowering and other medications. Clinicians also need to consider intensifying statin regimens, prescribing additional lipid-modifying therapies, and specific treatments aimed at triglyceride lowering to improve dyslipidemia control in statin-treated patients with T2DM.Keywords: triglycerides, lipid-lowering treatment, diabetic dyslipidemia, simvastatin, audit
format	article
author	Feher M Greener M Munro N
author_facet	Feher M Greener M Munro N
author_sort	Feher M
title	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
title_short	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
title_full	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
title_fullStr	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
title_full_unstemmed	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
title_sort	persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/4c3527219a6b492195168abc1ed0c729
work_keys_str_mv	AT feherm persistenthypertriglyceridemiainstatintreatedpatientswithtype2diabetesmellitus AT greenerm persistenthypertriglyceridemiainstatintreatedpatientswithtype2diabetesmellitus AT munron persistenthypertriglyceridemiainstatintreatedpatientswithtype2diabetesmellitus
_version_	1718403736387190784

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

Ejemplares similares